Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01172652 · ClinicalTrials.gov registry record · Phase 4
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
A Phase 4 study of Bipolar Disorder and Generalized Anxiety Disorder, sponsored by VA Palo Alto Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
- 3
- Study locations
NCT01172652: Completed Phase 4 study of Bipolar Disorder and Generalized Anxiety Disorder, sponsored by VA Palo Alto Health Care System.
NCT01172652 is a Phase 4 study of Bipolar Disorder and Generalized Anxiety Disorder that has completed, run by VA Palo Alto Health Care System. The registered enrollment target is 49 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01172652, a Phase 4 study of Bipolar Disorder and Generalized Anxiety Disorder, has completed, sponsored by VA Palo Alto Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
- 3
- Study locations
Study Summary
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of ziprasidone monotherapy in comparison to placebo in the treatment of ambulatory bipolar disorder with co-morbid lifetime panic disorder or generalized anxiety disorder and current at least moderately severe anxiety.
Primary Outcome
CGI-21 Anxiety Scale ranges from -10 (Very Bad. Could not be worse) to +10 (Major Improvement. Back to normal self).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ziprasidone
Study Locations (3)
California
- VA Palo Alto Health Care System & Stanford School of Medicine - Palo Alto
Florida
- University of South Florida Institute for Research in Psychiatry - Tampa
Ohio
- Lindner Center of Hope University of Cincinnati Medical Center - Mason
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
What the finished NCT01172652 record still lists
NCT01172652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01172652 reports a single indexed study location in California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT01172652 about?
NCT01172652 is a clinical study titled "Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)". The specific aim of this study is to evaluate the efficacy, tolerability, and safety of ziprasidone monotherapy in comparison to placebo in the treatment of ambulatory bipolar disorder with co-morbid lifetime panic disorder or generalized anxiety disorder and current at least moderately severe anxie...
What is the current status of trial NCT01172652?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2010-04. Estimated completion is 2011-10.
What conditions does trial NCT01172652 study?
This clinical trial studies the following conditions: Bipolar Disorder, Generalized Anxiety Disorder, Panic Disorder.
What interventions are being tested in trial NCT01172652?
The interventions under investigation include: Placebo (DRUG), Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT01172652?
This trial is sponsored by VA Palo Alto Health Care System, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01172652 being conducted?
This trial has 3 study locations across California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01172652's enrollment target sits among peer trials
49 114th of 162 higher than 48 of 162 other Bipolar Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
COMPLETED · Phase 4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
COMPLETED · Phase 4
-
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
COMPLETED · Phase 4
-
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
COMPLETED · Phase 4
-
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia